Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
GLOBETECH PUBLISHING
Schiller

Catheters in Dialysis Linked to High Risk of Infection

By HospiMedica International staff writers
Posted on 04 Mar 2013
A new study shows that dialysis patients using catheters for blood access have the highest risks for death, infections, and cardiovascular (CV) events.

Researchers at the University of Calgary (Canada), the University of Otago (Christchurch, New Zealand), and other institutions conducted a systematic review of cohort studies to evaluate the associations between type of vascular access (arteriovenous fistula, arteriovenous graft, and central venous catheter) and risk for death, infection, and major CV events. The researchers searched MEDLINE, EMBASE, and other article reference lists and extracted data describing study design, participants, vascular access type, clinical outcomes, and risk for bias. In all, 62 cohort studies comprising 586,337 participants met the inclusion criteria.

The results showed that when compared with patients with an arteriovenous fistula, those using catheters had a 38% higher risk of experiencing a major heart-related event, a 53% higher risk of dying, and more than twice the risk of developing fatal infections. Patients with arteriovenous grafts had an 18% increased risk of dying and a 36% increased risk of developing fatal infections compared to those with an arteriovenous fistula, but they did not have an increased risk of experiencing a major heart-related event. The study was published early online on February 21, 2013, in the Journal of the American Society of Nephrology (JASN).

“Our findings are reflected in current clinical practice guidelines, which promote fistulas as the preferred form of bloodstream access in hemodialysis patients,” said lead author Pietro Ravani, MD, of the University of Calgary, and colleagues. “Better quality data are needed, but not from studies with the same design as those already available. In fact, our cumulative meta-analysis shows that this information was already available 10 years ago.”

An arteriovenous fistula is currently the most recommended access for kidney disease patients who must undergo dialysis, created by connecting a patient's vein and artery to form a long-lasting site through which blood can be removed and returned. Alternatively, in patients who are unsuitable for a fistula, an arteriovenous graft—a plastic conduit between an artery and a vein—may be used. Many patients, however, prefer a catheter, for reasons that include inadequate preparation for dialysis, avoidance of surgery, or fear of needles (since the connection to the dialysis machine via a catheter does not require needles).

Related Links:

University of Calgary
University of Otago




ACEM
Cincinnati Sub-Zero
ECR

Channels

Women's Health

view channel

Aspirin Reduces Breast Cancer Recurrence in Overweight Women

The recurrence of hormone-related breast cancer was reduced by more than half in overweight and obese women who regularly used nonsteroidal anti-inflammatory drugs (NSAIDs), according to a new study. Researchers at the University of Texas (UT; Austin, USA) conducted a retrospective review of data from 440 women with... Read more

Health IT

view channel
Image: The BiliCam app reporting that bilirubin levels are normal (Photo courtesy of the University of Washington).

Smartphone app Detects Neonatal Jaundice in Minutes

A new smartphone app could serve as a screening tool to ascertain whether a baby needs a blood test to determine bilirubin levels. The BiliCam app, developed by researchers at the University of Washington... Read more

Business

view channel

Lloyds Bank Establishes Specialist Healthcare Teams

As part of a substantial restructure, Lloyds Bank Commercial Banking (London, United Kingdom) has launched two specialist healthcare relationship teams. Designated part of the small and medium enterprise (SME) commercial banking division, the two teams will offer industry-specific support for firms in London (United Kingdom).... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.